The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells
- PMID: 17890449
- DOI: 10.1182/blood-2007-05-092288
The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells
Abstract
Human herpesvirus-8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV), is etiologically linked to primary effusion lymphoma (PEL). At least 10 KSHV-encoded proteins with potential roles in KSHV-associated neoplasia have been identified. However, with few exceptions, these putative oncogenes were analyzed in heterologous systems only using overexpression of single genes. Thus, the pathogenetic relevance of most of these putative oncogenes remains essentially unclear. We used RNA interference (RNAi) to knock down the expression of several KSHV genes in cultured PEL cells carrying the KSHV genome. The viral interferon-regulatory factor-3 (vIRF-3) was found to be required for proliferation and survival of cultured PEL cells. Knock-down of vIRF-3 expression by various RNAi approaches unequivocally resulted in reduced proliferation and increased activity of caspase-3 and/or caspase-7. Thus, vIRF-3 can be seen as a bona fide oncogene of KSHV-associated lymphoma. Surprisingly, although the related Epstein-Barr virus (EBV) is usually sufficient to immortalize human B lymphocytes, silencing of vIRF-3 reduced the viability of both EBV(-) and EBV(+) PEL cells. This suggests that KSHV is the driving force in the pathogenesis of PEL.
Similar articles
-
Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.Antivir Ther. 2011;16(5):657-66. doi: 10.3851/IMP1810. Antivir Ther. 2011. PMID: 21817187 Free PMC article.
-
Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.mBio. 2020 Aug 25;11(4):e01457-20. doi: 10.1128/mBio.01457-20. mBio. 2020. PMID: 32843547 Free PMC article.
-
Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11379-E11387. doi: 10.1073/pnas.1810128115. Epub 2018 Nov 14. Proc Natl Acad Sci U S A. 2018. PMID: 30429324 Free PMC article.
-
[Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8)].Uirusu. 2010 Dec;60(2):237-45. doi: 10.2222/jsv.60.237. Uirusu. 2010. PMID: 21488336 Review. Japanese.
-
Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.Adv Exp Med Biol. 2018;1045:357-376. doi: 10.1007/978-981-10-7230-7_16. Adv Exp Med Biol. 2018. PMID: 29896675 Review.
Cited by
-
KSHV-Mediated Angiogenesis in Tumor Progression.Viruses. 2016 Jul 20;8(7):198. doi: 10.3390/v8070198. Viruses. 2016. PMID: 27447661 Free PMC article. Review.
-
Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma.Cancers (Basel). 2020 Sep 1;12(9):2483. doi: 10.3390/cancers12092483. Cancers (Basel). 2020. PMID: 32883022 Free PMC article.
-
Optimizing treatment of HIV-associated lymphoma.Blood. 2019 Oct 24;134(17):1385-1394. doi: 10.1182/blood-2018-01-791400. Blood. 2019. PMID: 30992269 Free PMC article. Review.
-
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.Blood. 2018 Aug 9;132(6):577-586. doi: 10.1182/blood-2018-01-828418. Epub 2018 Jun 28. Blood. 2018. PMID: 29954751 Free PMC article.
-
Epigenetic control in Kaposi sarcoma-associated herpesvirus infection and associated disease.Semin Immunopathol. 2020 Apr;42(2):143-157. doi: 10.1007/s00281-020-00787-z. Epub 2020 Mar 26. Semin Immunopathol. 2020. PMID: 32219477 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials